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Expanded-spectrum 
β-Lactamase and 
Plasmid-mediated 
Quinolone 
Resistance 
To the Editor: The emergence of 
plasmid-mediated, and thus transfer-
able, quinolone resistance determi-
nants has been recently discovered (1) 
and shown to involve the pentapeptide 
repeat protein Qnr, which interacts with 
DNA gyrase and topoisomerase IV to 
prevent quinolone inhibition (2,3). 
Qnr determinants confer resistance to 
nalidixic acid and reduced susceptibil-
ity to ﬂ  uoroquinolones (3). They have 
been identiﬁ  ed worldwide in a variety 
of enterobacterial species and were of-
ten associated to expanded-spectrum 
β-lactamases (ESBLs) (2). The asso-
ciation between the ESBL VEB-1 and 
the QnrA1 determinants was reported 
(4). Because plasmid co-localization 
of QnrA and VEB-1 encoding genes 
has been reported repeatedly from 
scattered clonally-unrelated entero-
bacterial isolates, our objective was to 
use replicon typing to trace a possible 
dissemination of a common plasmid 
worldwide.
The blaVEB-1- and/or qnrA-positive 
plasmids that have been included in 
the study were from 17 isolates previ-
ously described in detail (3–8) (Table). 
Escherichia coli transconjugants (Tc) 
were obtained for 14 of 17 clinical 
isolates, allowing an accurate replicon 
typing since original clinical isolates 
might harbor several plasmids. They 
were collected from 1999 to 2005, 
from patients hospitalized in differ-
ent parts of the world (Table). The 13 
blaVEB-1-positive isolates were from 5 
countries (France, Turkey, Algeria, 
Thailand, and Canada), scattered on 
4 continents. Among them, the Provi-
dencia stuartii and Proteus mirabilis 
isolates from Algeria were negative 
for qnrA1. In addition, 4 blaVEB-1-nega-
tive but qnrA1-positive isolates recov-
ered from France and Australia were 
also included in the study.
PCR-based replicon typing 
(PBRT), which recognizes FIA, FIB, 
FIC, HI1, HI2, I1-Iγ, L/M, N, P, W, 
T, A/C, K, B/O, X, Y, and FII repli-
cons (9), was applied to type the re-
sistance plasmids from all the strains. 
Table. Features of the VEB-1– or QnrA-positive isolates used in this study* 
Strain† (Ref.)  Sp. of origin  Country 
Year of 
isolation
Plasmid
size (kb)  ESBL QnrA1 Replicon
Resistance
markers‡
Escherichia coli
TcE1 (5)
E. coli Thailand 1999 160 VEB-1 + A/C2 NAL, K, SSS, C, 
RA
E. coli TcE4 (5) E. coli Thailand 1999 150 VEB-1 + A/C2 NAL, K, TM, SSS, 
C, RA 
E. coli TcE5 (5) E. coli Thailand 1999 150 VEB-1 + A/C2 NAL, K, TM, SSS, 
SXT
E. coli TcE7 (5) E. coli Thailand 1999 150 VEB-1 + A/C2 NAL, K, TM, SSS, 
C, RA 
E. coli TcE8 (5) E. coli Thailand 1999 150 VEB-1 + A/C2 NAL, K, TM, SSS, 
TE
E. coli TcE16 (5) E. coli Thailand 1999 140 VEB-1 + A/C2 NAL, K, TM, SSS, 
RA
E. coli TcE18 (5) E. coli Thailand 1999 180 VEB-1 + A/C2 NAL, K, SSS,
C, RA 
E. coli Tc(p1) (5) E. coli Canada 2000 180 VEB-1 + A/C2 NAL, K, SSS,
C, RA 
E. coli Tc(pQR1) 
(4)
E. coli France 2003 180 VEB-1 + A/C2 NAL, K, SSS,
C, RA, SXT 
E. coli Tc(GOC) (4) Enterobacter
cloacae
France 2003 190 VEB-1 + A/C2, FIB  NAL, K, TM,
SSS, C 
Citrobacter freundii
LUT (3)
C. freundii Turkey 2004 ND VEB-1 + A/C2, FIB, 
K
NA
Providencia stuartii
15 (this study) 
P. stuartii Algeria 2004 ND VEB-1 – A/C2 NA
E. coli TcMAA (this 
study) 
Proteus
mirabilis
Algeria 2004 190 VEB-1 – A/C2 K, TM, SSS,
C, SXT 
E. coli TcK147 (7) Klebsiella
pneumoniae
Australia 2002 160 SHV-12 + HI2, A/C1,
P
NAL, K, TM, C, 
TE, SXT 
E. cloacae A1 (8) E. cloacae France 2004 75 SHV-12 + HI2 NA
E. coli TcA2 (8) Enterobacter
aerogenes
France 2005 150 SHV-12 + FII NAL, K, TM, TE 
E. coli TcA3 (8) K. pneumoniae  France 2005 40 – + I1, K  NAL, K, TM, C, TE
*Ref., reference; ESBL, expanded-spectrum β-lactamase; NAL, nalidixic acid; K, kanamycin; SSS, sulfonamides; C, chloramphenicol; RA, rifampin; TM, 
tobramycin; SXT, trimethoprim-sulfamethoxazole; TE, tetracycline; ND, not determinable; NA, not applicable. 
†Tc indicates that this is a transconjugant or a transformant.  
‡Non–β-lactam–associated markers. LETTERS
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Amplicons were conﬁ  rmed by DNA 
sequencing and used as probes in hy-
bridization experiments on puriﬁ  ed 
plasmids (data not shown).
PBRT results showed that the 13 
blaVEB-1-positive plasmids (including 
11  qnrA1-positive) belonged to the 
IncA/C incompatibility group. DNA 
sequencing identiﬁ  ed the A/C2 repli-
con variant (European Molecular Bi-
ology Laboratory no. AM087198) in 
all these plasmids (Table). Plasmids of 
this type were recently identiﬁ  ed in the 
United States and in Italy carrying the 
AmpC-type cephalosporinase CMY-
2–encoding gene (10). In 2 strains (E. 
coli TcGOC and Citrobacter freundii 
LUT), the IncA/C2 plasmids were as-
sociated with additional replicons, 
which suggests the presence of mul-
tiple plasmids or fusions between 
plasmids of different backbones. By 
contrast, all the 4 blaVEB-1-negative 
isolates but qnrA1-positive were nega-
tive for the A/C replicon, except trans-
conjugant TcK147; however, sequenc-
ing identiﬁ  ed  an A/C1-type replicon 
in that strain. These results indicated 
that the genes encoding QnrA1 and 
VEB-1, when identiﬁ  ed  concomi-
tantly in a given isolate, were always 
located on plasmids belonging to the 
same IncA/C2-incompatibility group 
that may vary in size and digestion 
pattern (Table; unpub. data). In addi-
tion, we showed that plasmids carry-
ing the blaVEB-1 gene but lacking qnrA1 
were also of the IncA/C2 type (Table). 
Plasmids that were blaVEB-1-negative 
but  qnrA1-positive were of distinct 
replicon types, thus suggesting inde-
pendent acquisition of the qnrA1 gene 
on different plasmids. It is remarkable 
that since VEB-1 is apparently always 
encoded by IncA/C2 plasmids, when 
genes for QnrA1 and VEB-1 are found 
together, they also occur on IncA/C2 
plasmids.
Thus, evidence here shows that 
the IncA/C2 plasmid is the main vehi-
cle of the blaVEB-1 gene worldwide, on 
which the qnrA1 gene may be added. 
The possibility that both blaVEB-1 and 
qnrA1 genes may be identiﬁ  ed on a 
single genetic structure in several iso-
lates has been recently shown with 
their identiﬁ   cation within the same 
sul1-type integron (6).
Because results of these experi-
ments provided a good marker for 
tracing blaVEB-1-positive plasmids, and 
taking in account the property of A/C-
type plasmids to have a broad range of 
hosts (note: this has not been demon-
strated for the speciﬁ  c A/C2 subgroup), 
we tried to amplify the A/C2 replicon in 
a collection of 15 blaVEB-1-positive and 
clonally unrelated Pseudomonas aeru-
ginosa isolates from France, Thailand, 
India, and Kuwait. The blaVEB-1 gene 
was supposed to be chromosome-en-
coded in those isolates. PCR failed to 
give any positive results, conﬁ  rming 
the absence of an IncA/C-type plas-
mid and also ruling out the hypothesis 
of IncA/C2-type plasmid co-integra-
tion at the origin of blaVEB-1 acquisition 
in P. aeruginosa.
The spread of plasmids carrying a 
large array of resistance genes among 
Enterobacteriaceae is of concern 
since this provides a convenient ge-
netic mechanism for a given strain to 
become panresistant to antimicrobial 
drugs. In particular, the recent iden-
tiﬁ  cation of the Qnr determinants has 
shown that plasmids may provide re-
sistance (or at least reduced suscepti-
bility) to quinolones and ﬂ  uoroquino-
lones, whereas they are already known 
to carry resistance to β-lactams, ami-
noglycosides, chloramphenicol, tetra-
cycline, rifampin, sulfonamides, and 
disinfectants. pQR1 (4) or p1 (6) are 
examples of well-characterized plas-
mids that mediate multidrug resis-
tance by carrying blaVEB-1 and qnrA1,  
together with aminoglycoside resis-
tance genes aadB, aacA1, and aadA1, 
chloramphenicol resistance gene 
cmlA, rifampin resistance gene arr2, 
disinfectant resistance gene qacI, and 
sulfonamides resistance gene sul1.
Our study showed that the IncA/
C2-type plasmids may be the source 
of such worldwide dissemination. It 
means that 1 plasmid scaffold has 
brought the same (or at least very sim-
ilar) multidrug resistance to multiple 
enterobacterial species in different 
continents.
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Viral Load and 
Crimean-Congo 
Hemorrhagic Fever 
To the Editor: Crimean-Congo 
hemorrhagic fever (CCHF) is a severe 
viral disease transmitted to humans 
by tick bite or contact with blood, ex-
creta, or tissues of infected patients or 
livestock. The disease is endemic in 
many African, Asian, and European 
countries. Sporadic cases or outbreaks 
have been observed in the Balkan 
Peninsula (1–5). Prompt diagnosis of 
the disease is essential for preventing 
human-to-human transmission. Re-
verse transcription–PCR (RT-PCR) 
is the detection method of choice in 
ﬁ  rst days of illness and in severe cases 
with no antibody production. In recent 
years, real-time RT-PCR approaches 
have been described for detection and 
quantiﬁ   cation of CCHF virus (6–8). 
However, no information is available 
on viral RNA concentration in patients. 
We describe a real-time RT-PCR for 
detection and quantiﬁ  cation of CCHF 
virus, present the results of its use with 
clinical samples, and report the rela-
tionship between viral load and sever-
ity and outcome of CCHF.
We tested 29 serum samples from 
Albanian patients with suspected 
CCHF or their contacts who were liv-
ing in a CCHF-endemic area of Al-
bania. Serum samples were collected 
during 2003–2006 and categorized 
into 3 groups. Group A contained 
samples from 11 patients with CCHF 
conﬁ  rmed by a conventional RT-nest-
ed PCR (9). Group B contained sam-
ples from 5 patients who had negative 
RT-nested PCR results and positive 
serologic results. Group C contained 
samples from 15 persons who were 
from the same region as the CCHF pa-
tients but who did not have any clini-
cal symptoms of CCHF and had nega-
tive PCR or serologic results.
One set of primers and 1 probe 
were designed to amplify an 84-bp 
genome region of the S RNA segment 
of CCHF virus on the basis of Euro-
pean sequences (Balkan and Russian 
strains available in GenBank): primers 
CCEuS 5′-TGACAGCATTTCTTTA-
ACAGACATCA-3′ and CCEuAs 5′-
AAACACGGCAGCCTTAAGCA-3′, 
and probe 5′-TCGCCAGGGACTT-
TATATTCTGCAAGG-3′. A 25-μL 
reaction was conducted in a LightCy-
cler (Roche, Indianapolis, IN, USA) 
with 10 mmol/L of each deoxynucleo-
tide triphosphate, 600 nmol/L of each 
primer, 200 nmol/L of probe, and 3 
μL of RNA. Cycling conditions were 
50°C for 30 min and 95°C for 15 min, 
followed by 45 cycles at 95°C for 15 
s and 58°C for 30 s. A quantiﬁ  cation 
curve was constructed with 10-fold 
serial dilutions of in vitro–transcribed 
CCHF virus RNA. Positive results 
were obtained up to a dilution of 10−12, 
which corresponds to ≈45 virus ge-
nome equivalents (geqs) per reaction.
Twelve samples had positive re-
sults: all 11 samples in group A and 
1 in group B (Table). Results for the 
remaining samples in groups B and 
C were negative. Levels of tumor ne-
crosis factor-α (TNF-α), interleukin-6 
(IL-6), IL-10, and a 60-kDa soluble 
receptor of TNF were previously mea-
sured in most of the samples in this 
study (10), and their values are shown 
in the Table.
Viral loads ranged from 14 × 
106 to 28.99 × 106 geqs/reaction. The 
highest level was observed in the pa-
tient who died (23/03). High loads 
were observed in all primary case-pa-
tients (23/03, 82/03, 178/04, 252/06) 
except for patient 154/04, from whom 
a sample was obtained 18 days after 
onset of disease. All primary case-
patients had severe disease with high 
fever and clinically apparent hemor-
rhage. All secondary case-patients, 
except patient 34/03, were contacts 
of the patient who died (24b/03, hus-
band; 25b/03, brother-in-law; 50/03 
and 52/03, cousins; 56/03, sister-
in-law; 40/03, son of sister) and had 
symptoms of disease ≈1 week after the 
death of patient 23/03. 
Viral load of secondary case-pa-
tients was <250 geqs/reaction, which 
was much lower than that of primary 
case-patients. This ﬁ  nding  suggests 
that the disease is more severe in 
primary case-patients and becomes 
a milder form in secondary case-pa-
tients. Samples of secondary case-
patients 24b/03 and 25b/03 were ob-
tained on day 9 of illness, and patient 
24b/03 had a 4× higher viral load than 
patient 25b/03. A possible explanation 
might be that because patient 24b/03 
had closer contact with the person 
who died, he received a higher dose 
of virus, which might affect severity 
of the disease. Other secondary case-
patients had milder symptoms with no 
clinically apparent hemorrhage and 
were not hospitalized. All hospitalized 
patients had leukopenia, except for 
the patient whose sample was taken 
18 days after the onset of disease. No 
correlation was observed between vi-
ral load and cytokine levels or platelet 
counts, which suggests that other fac-
tors are involved in pathogenicity and 
immune response.